Research programme: metastatic breast cancer therapy - Chugai

Drug Profile

Research programme: metastatic breast cancer therapy - Chugai

Alternative Names: CH 4893237

Latest Information Update: 22 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chugai Biopharmaceuticals; Immusol
  • Developer Chugai Biopharmaceuticals; iTherX Pharmaceuticals
  • Class Estradiol congeners
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer metastases

Most Recent Events

  • 24 Aug 2007 This programme is still in active development
  • 26 Jan 2005 Data presented at the 27th Annual San Antonio Breast Cancer Symposium (SABCS-2004) have been added to the Cancer pharmacodynamics section
  • 04 Nov 2002 Chungai Pharmaceutical has been acquired by Roche
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top